InterVenn Biosciences Achieves Milestone with AMA Code for Ovarian Cancer Diagnostic

What's Happening?

InterVenn Biosciences has received a Proprietary Laboratory Analysis (PLA) code from the American Medical Association for its GlycoKnow Ovarian test. This non-invasive diagnostic differentiates between cancerous and benign pelvic masses, aiding in treatment planning. The test will be commercially available in the fall, coinciding with the coding effective date of October 1, 2025. The PLA code facilitates billing and potential insurance reimbursement, accelerating clinical integration.

Why It's Important?

The PLA code represents a significant advancement in women's health diagnostics, providing a non-invasive option for ovarian cancer detection. This development could reduce unnecessary procedures and improve patient outcomes by enabling more precise treatment planning. The test's integration into routine clinical care could enhance access to innovative diagnostics, benefiting patients, healthcare providers, and the medical system.

What's Next?

InterVenn plans to launch GlycoKnow Ovarian commercially in the fall, with efforts to integrate the test into clinical care across the U.S. healthcare system. The company is also offering an early access program for healthcare providers interested in utilizing the test. This initiative aims to improve diagnostic pathways for women and enhance the precision of ovarian cancer detection.